Prospective Comparison of PET Imaging with PSMA-targeted 18F-DCFPyL versus Na18F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer.
Purpose: Bone metastases in prostate cancer (PCa) have important prognostic significance and imaging modalities used for PCa staging should have high sensitivity for detecting such lesions. Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) radiotracers are promising new agents for imaging PCa. We undertook a head-to-head comparison of PSMA-targeted 18F-DCFPyL PET to Na18F PET to determine which modality was more sensitive for the detection of lesions suspicious for bone metastases in a group of patients with metastatic PCa. Materials and Methods: Patients with progressive, metastatic PCa were prospectively imaged with both 18F-DCFPyL and Na18F PET/CT, with both scans occurring within 24 hours of each other. A consensus, 2-reader central review was carried out to identify all bone lesions suspicious for sites of PCa involvement on both scans and maximized standardized uptake values corrected for weight (SUVmax) and lean body mass (SULmax) were recorded. Soft tissue lesions were also noted on both scans and SUVmax, SULmax, and PSMA-RADS version 1.0 scores were recorded. Data from the two scans was compared using a generalized estimating equation. Results: In total, 16 patients meeting all inclusion criteria were enrolled in this study and 15/16 (93.8%) were imaged with both PET radiotracers. A total of 405 bone lesions suspicious for sites of PCa were identified on at least one scan. On 18F-DCFPyL PET/CT, 391 (96.5%) were definitively positive, 4 (1.0%) were equivocally positive, and 10 (2.5%) were negative. On Na18F PETCT, the corresponding values were 388 (95.8%), 4 (1.0%), and 13 (3.2%). Of the definitively negative lesions on 18F-DCFPyL PET, 8/10 (80.0%) were sclerotic and 2/10 (20.0%) were infiltrative/marrow-based. Additionally, 12/13 (92.3%) of the definitively negative lesions on Na18F PET were infiltrative/marrow-based and 1/13 (7.7%) was lytic. 78 PSMA-RADS-4, 17 PSMA-RADS-5, and 1 PSMA-RADS-3C soft tissue lesions were also identified. Conclusion: PET/CT imaging using 18F-DCFPyL and Na18F PET had nearly identical sensitivities for the detection of bone lesions in patients with metastatic PCa. As would be expected, PSMA-targeted PET provides more information on soft tissue disease. There may be little additional value to imaging patients with PCa with Na18F after a PSMA-targeted PET scan has already been performed.